Omrix Biopharmaceuticals, a New York-based biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, has received FDA approval for its Evicel™ liquid fibrin sealant for use in vascular surgery.

“We are expanding the commercialization potential of our hemostasis franchise with Evicel’s expanded indication in vascular surgery,” says Robert Taub, president and CEO of Omrix Biopharmaceuticals. “We are also one step closer to obtaining a general hemostasis in surgery indication for Evicel, and reaching our stated objective of creating a one-stop shop for biological hemostats.”

Ethicon Inc, the company’s marketing partner, will promote Evicel’s vascular indication to surgeons for procedures in which a vascular anastomosis or reconstruction is performed. According to the company, the product will be marketed to peripheral vascular surgeons, cardiac surgeons (for vascular components), plastic surgeons performing microvascular anastomoses, transplant surgeons (for connecting blood vessels), and trauma surgeons performing vascular repair.

Evicel will be marketed in the first quarter of 2008.

[Business Wire, May 15, 2007]